Please type a plus sign (+) inside this box → [+]

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/505,377
Filing Date	October 20, 2004
First Named Inventor	Lobanenkov
Group Art Unit	1642
Examiner Name	Anne Gussow
Attorney Docket Number	230295

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document: Application or Patent Number	U.S. Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document: Office	Foreign Patent Document: Application or Patent Number	Foreign Patent Document: Kind Code	Name of Patentee or Applicant	Date of Publication	Translation: Yes	Translation: No*+

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation: Yes	Translation: No*+
	B W	D'ARCY et al., "The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis," *Clin. Cancer Res.*, *12 (20)*, pp 5978 - 5986, (October 15, 2006).		
	B X	RISINGER et al., "Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression," *Clin. Cancer Res.*, *13 (6)*, pp 1713-1719, (March 15, 2007)		

Examiner Signature		Date Considered	

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

\+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).